Find in Library

Nitika,1,2 Jiao Wei,1,2 Ai-Min Hui1,2 1Fosun Pharma USA Inc., Boston, MA, USA; 2Shanghai Fosun Pharmaceutical Industrial Development, Co., Ltd., Shanghai, People’s Republic of ChinaCorrespondence: Ai-Min HuiShanghai Fosun Pharmaceutical Industrial Development, Co., Ltd., 1289 Yishan Road, Shanghai, 200233, People’s Republic of ChinaTel +86-21-33987000Fax +86-21-33987020Email aimin.hui@fosunpharma.comAbstract: mRNA-based technologies have been of interest for the past few years to be used for therapeutics. Several mRNA vaccines for various diseases have been in preclinical and clinical stages. With the outbreak of the COVID-19 pandemic, the emergence of mRNA vaccines has transformed modern science. Recently, two major mRNA vaccines have been developed and approved by global health authorities for administration on the general population for protection against SARS-CoV-2. They have been proven to be successful in conferring protection against the ongoing SARS-CoV-2 and its emerging variants. This will draw attention to various mRNA vaccines against infectious diseases that are in the early stages of clinical trials. mRNA vaccines offer several advantages ranging from rapid design, generation, manufacturing, and administration and have strong potential to be used against various diseases in the future. Here, we summarize the mRNA-based vaccines in development against various infectious diseases.Keywords: vaccines, mRNA, infectious diseases, lipid nanoparticles, immune response